Navigation Links
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
Date:10/24/2007

- favorable pharmacokinetic and safety data observed in first clinical

trial of novel Fleximer(TM) anticancer agent -

CAMBRIDGE, Mass., Oct. 24 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and Associate Director for Clinical Research, University of Maryland Greenebaum Cancer Center in a poster session on October 23 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics taking place in San Francisco, CA. Full text of the abstract #A146 "A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients with Advanced Solid Tumors" can be viewed online at the AACR website at http://www.aacr.org. XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity.

Commenting on the data, Robert J. Fram, M.D. Chief Medical Officer at Mersana, stated: "The Phase I results show that, in humans, camptothecin, the active agent in XMT-1001, is released gradually from the Fleximer carrier as a pro-drug in a manner that will potentially avoid common safety problems associated with drugs in this class. To date, we've seen no evidence of drug-related serious adverse events and the study is ongoing."

Results were presented from 12 patients enrolled in an ongoing Phase I open-label, dose-escalation trial designed to determine the safety, tolerability and pharmacokinetic profile of XMT-1001. To date, XMT-1001 has been well tolerated in patients and no serious drug related adverse events have been reported. Preliminary results demonstrate a favorable pharmacokinetic profile with low levels of CPT, both total and free, recovered in urine. The ma
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Conn. , Oct. 17, 2014  UBM Medica ... online community for endocrinologists and other clinicians who treat ... comprehensive coverage on effective use of insulin .  ... eventually require insulin replacement therapy – daily ... for the progressive decline in the function of pancreatic ...
(Date:10/17/2014)...  Ameritox SM , the nation,s leader in medication ... Smith , M.D., as Chief Medical Officer. In this ... resources for healthcare providers, patients and managed care plans. ... a variety of healthcare companies that have provided him ... behavioral health sides of Ameritox,s business. He most recently ...
(Date:10/17/2014)... Oct. 17, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro® ... Healthcare Center , a 140,000 square foot, 44-bed hospital ... hospital serves a large number of Native ... Oklahoma and beyond. A portion of its ...
Breaking Medicine Technology:Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... 2014 Stephen T. Greenberg, M.D., with offices ... the 10th consecutive year as one of Long Island’s best ... also been nominated as the best provider for Botox injections. ... best Day Spa and best Laser Treatment center on Long ... readers can vote for the contest once per day, per ...
(Date:10/19/2014)... – The U.S. Government has initiated a major ... by 2025. However, a workgroup of nearly 40 ... in the U.S. Government,s National Plan to Address ... in scale, and adequately funded in order to ... by the workgroup to enlarge and strengthen the ...
(Date:10/19/2014)... One major trend in the market is ... high-cost structure leading to the implementation of more proton ... the Global Proton Therapy market to grow ... 2013-2018. According to the report, one of the main ... medical diagnostics and therapeutics. The advances in technology led ...
Breaking Medicine News(10 mins):Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4
... The American School,Health Association, the National Association of ... today joined together to create,one voice to urge ... Prevention,and Tobacco Control Act, which would give the ... three associations, each formed to assist the Nation,s ...
... representatives are invited,to a photo opportunity with the Honourable ... Governor, in light of an,international collaboration announcement on cancer ... Convention in San Diego., Who: ... Arnold Schwarzenegger, The ...
... Inc.,(Nasdaq: HOLX ) today announced that Glenn Muir, ... Annual Healthcare Conference being,held June 24 - 26, 2008, ... Interested parties are invited to listen to a ... 25, 2008, at 12:30 PM.,Eastern Time on the investor ...
... also express concern about psoriasis drug,s possible risks for ... strengthening , , WEDNESDAY, June 18 (HealthDay News) -- ... Wednesday that the psoriasis drug Enbrel be approved for ... skin disease. , The outside medical experts, in a ...
... higher annual volumes of patients with inflammatory bowel disease ... than hospitals with lower volumes of IBD patients, according ... College of Wisconsin in Milwaukee. ,The study ... for patients who undergo surgery for Crohn,s Disease, a ...
... SF-12v2 Health Survey Results are Used to Measure Physical ... and Mental Health Status of Program Participants, ... the,SilverSneakers(R) Fitness Program was created to encourage older adults ... the nation,s leading,fitness program aimed exclusively at older adults. ...
Cached Medicine News:Health News:Major Associations Band Together to Urge Congressional Action on Tobacco Legislation 2Health News:Hologic to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 3Health News:Choice of hospital impacts outcomes for inflammatory bowel disease surgery 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 3
... Stryker BioZip Suture Anchor is a unique double ... BioZip is made from Poly-L Lactic Acid (PLLA) ... Needles are attached to the suture ends for ... arthroscopic repairs. The trocar tip inserter allows insertion ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
... AnchorSew™ 3 mm is a resorbable repair device ... ArthroSew suturing device to attach soft tissue to ... into a prepared hole in the bone, and ... tissue anchors are made of a resorbable copolymer, ...
... is generally used when anchor size ... anchor is packaged sterile and comes ... and needles. Although pre-drilling is not ... Harpoon®, 1.6mm & 1.8mm drills are ...
Medicine Products: